









Markets
/
Stocks
/
nasdaq-siga
/

SIGA Technologies Inc

SIGA

8.870USD

+0.210+2.42%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

634.56MMarket Cap

7.72P/E TTM



SIGA Technologies Inc

8.870

+0.210+2.42%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

69 / 175

Overall Ranking

195 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 25.23% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 74.65.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 72.80%.

Fairly Valued

The company’s latest PE is 7.70, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 67.74M shares, decreasing 5.38% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.48M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.00.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.54, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 81.12M, representing a year-over-year increase of 271.92%, while its net profit experienced a year-over-year increase of 1836.20%.

Score

Industry at a Glance

Previous score

9.54

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.17

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.52

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 4.07, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 7.52, which is 13.94% below the recent high of 8.57 and 29.80% above the recent low of 5.28.

Score

Industry at a Glance

Previous score

4.07

Change

-0.06

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 7.16, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 9.18 and the support level at 8.17, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.16

Change

1.62

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.066

Neutral

RSI(14)

56.970

Neutral

STOCH(KDJ)(9,3,3)

62.833

Neutral

ATR(14)

0.317

High Vlolatility

CCI(14)

33.751

Neutral

Williams %R

31.183

Buy

TRIX(12,20)

0.362

Sell

StochRSI(14)

46.834

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

8.888

Sell

MA10

8.807

Buy

MA20

8.686

Buy

MA50

7.984

Buy

MA100

7.044

Buy

MA200

6.242

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 94.60%, representing a quarter-over-quarter decrease of 1.18%. The largest institutional shareholder is The Vanguard, holding a total of 2.48M shares, representing 3.46% of shares outstanding, with 0.14% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

MacAndrews & Forbes Holdings, Inc.

24.16M

Lewis (John Latane IV)

5.27M

BlackRock Institutional Trust Company, N.A.

3.15M

-2.07%

AltraVue Capital, LLC.

2.40M

-9.19%

The Vanguard Group, Inc.

Star Investors

2.48M

+0.44%

Dimensional Fund Advisors, L.P.

2.35M

+10.67%

Hotchkis and Wiley Capital Management, LLC

Star Investors

3.16M

+52.93%

American Century Investment Management, Inc.

1.37M

+7.76%

Citadel Advisors LLC

1.16M

+10.35%

State Street Global Advisors (US)

1.11M

-4.30%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 5.06, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.